drugset

drugset / Trial / NCT00097721

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

NCT00097721 ↗

Phase 2 Completed 104 enrolled Eisai Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if E7389 is a safe and effective treatment for advanced/metastatic breast cancer.

Timeline

Start: 2004-09
Primary completion: 2006-11
Completion: 2006-11

Publications

Muss H, Cortes J, Vahdat LT, Cardoso F, Twelves C, Wanders J, Dutcus CE, Yang J, Seegobin S, O'Shaughnessy J. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist. 2014 Apr;19(4):318-27. doi: 10.1634/theoncologist.2013-0282. Epub 2014 Mar 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eribulin	Small molecule	1.4 mg/m2	Intravenous

Indications